| GTO ID | GTC3590 |
| Trial ID |
NCT06045806
|
| Disease |
Multiple Myeloma
|
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Abecma|bb2121|BMS-986395|Idecabtagene vicleucel|ide-cel |
| Co-treatment | Lenalidomide |
| Location approved | US, Canada, EU, UK, Japan, Israel, Switzerland |
| Phase | Phase3 |
| Recruitment status | Recruiting |
| Title | A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9) |
| Year | 2023 |
| Country | Australia|Austria|Belgium|Canada|Czechia|Denmark|France|Germany|Greece|Israel|Italy|Japan|Korea, Republic of|Norway|Poland|Romania|Spain|United Kingdom|United States |
| Company sponsor | Celgene |
| Other ID(s) | CA089-1043|2022-501346-30|U1111-1280-9736 |